Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › gemcitabine

gemcitabine

21 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of gemcitabine

370 trials tracked of gemcitabine: 64 in phase 3 or 4 and 39 with published results. The most-cited published study has 2894 citations.

370Trials tracked
64Phase 3 & 4
0Recruiting
39With published results
Phase distribution
Phase 3 64 Phase 2 281 Phase 1 23 Other / NA 2
  1. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,894 cited
  2. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,588 cited
  3. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Completed · 1,846 cited
  4. Phase 3 A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] Completed · 1,726 cited
  5. Phase 3 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed · 1,169 cited
  6. Phase 3 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) Completed · 1,127 cited
Show 44 more trials
  1. Phase 3 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Completed · 798 cited
  2. Phase 3 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Completed · 659 cited
  3. Phase 3 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Completed · 505 cited
  4. Phase 3 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment Completed · 488 cited
  5. Phase 3 First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin Completed · 479 cited
  6. Phase 3 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer Completed · 461 cited
  7. Phase 3 Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC Completed · 324 cited
  8. Phase 3 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed · 241 cited
  9. Phase 3 Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) Completed · 226 cited
  10. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 219 cited
  11. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 195 cited
  12. Phase 3 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed · 192 cited
  13. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 183 cited
  14. Phase 3 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Completed · 173 cited
  15. Phase 3 Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Completed · 172 cited
  16. Phase 3 A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Completed · 166 cited
  17. Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 166 cited
  18. Phase 3 A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy Completed · 164 cited
  19. Phase 3 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Completed · 157 cited
  20. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 144 cited
  21. Phase 3 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Completed · 139 cited
  22. Phase 3 Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) Completed · 115 cited
  23. Phase 3 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Completed · 60 cited
  24. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Completed · 58 cited
  25. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 54 cited
  26. Phase 3 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) Completed · 46 cited
  27. Phase 3 The Bladder Instillation Comparison Study Completed · 39 cited
  28. Phase 3 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma Completed · 37 cited
  29. Phase 3 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed · 37 cited
  30. Phase 3 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine Completed · 24 cited
  31. Phase 3 Avelumab in First-line NSCLC (JAVELIN Lung 100) Completed · 23 cited
  32. Phase 3 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study Completed · 14 cited
  33. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  34. Phase 3 A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Completed
  35. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  36. Phase 3 Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Completed
  37. Phase 3 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed
  38. Phase 3 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Completed
  39. Phase 3 EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Completed
  40. Phase 3 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma Completed
  41. Phase 3 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer Completed
  42. Phase 3 A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed
  43. Phase 3 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Completed
  44. Phase 3 Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC Completed

Showing the 50 most-cited and recently-updated of 370 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Trastuzumab emtansine and sintilimab combination shows lesion size reduction in HER2-positive metastatic gallbladder adenocarcinoma
Neurology Sys. Review
Trastuzumab emtansine and sintilimab combination shows lesion size reduction in HER2-positive metastatic gallbladder adenocarcinoma New drug combination shows promise for certain gallbladder cancer
This case report and literature review describes a 46-year-old male with HER2-positive metastatic gallbladder adenocarcinoma treated with tr…
A new treatment combination involving trastuzumab emtansine and sintilimab helped shrink tumors in a patient with a specific type of gallbla…
Frontiers Sep 10, 2026
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
medRxiv Aug 28, 2026
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients
Oncology RCT
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients Radiotherapy shows promise for specific pancreatic cancer patients
This Phase III multicenter randomized controlled trial of 354 patients with adenocarcinoma of the pancreatic head found no significant diffe…
Adding radiation to chemotherapy may improve survival and stay disease-free for certain patients with pancreatic head cancer.
Aug 22, 2026
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL
Hematology RCT
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL Trial shows promising results for relapsed large B-cell lymphoma
This Phase III randomized controlled trial analyzed a subgroup of 16 Japanese patients with relapsed or refractory large B-cell lymphoma. Th…
A new treatment combination showed a high response rate and longer progression-free survival for patients with a specific type of lymphoma.
Aug 2, 2026
Neoadjuvant gemcitabine plus nab-paclitaxel vs gemcitabine plus S-1 for geriatric pancreatic cancer
Oncology RCT
Neoadjuvant gemcitabine plus nab-paclitaxel vs gemcitabine plus S-1 for geriatric pancreatic cancer Trial tests two chemo combos for older pancreatic cancer patients
This Phase III randomized controlled trial is evaluating neoadjuvant gemcitabine plus nab-paclitaxel compared to gemcitabine plus S-1 in 400…
A new trial compares two chemotherapy combinations for older adults with resectable pancreatic cancer.
Jul 12, 2026
Intravesical gemcitabine and docetaxel provide effective treatment for high-risk non-muscle-invasive bladder cancer
Oncology Meta-analysis
Intravesical gemcitabine and docetaxel provide effective treatment for high-risk non-muscle-invasive bladder cancer Sequential gemcitabine and docetaxel show promise for bladder cancer
This systematic review and meta-analysis of 883 patients evaluated the efficacy and safety of intravesical sequential gemcitabine and doceta…
A new treatment combination involving two drugs may offer an effective way to manage high-risk bladder cancer while remaining well tolerated…
Frontiers Jul 9, 2026
Multidisciplinary management of mixed adenoneuroendocrine carcinoma of the gallbladder involves surgery and adjuvant chemotherapy
Oncology Meta-analysis
Multidisciplinary management of mixed adenoneuroendocrine carcinoma of the gallbladder involves surgery and adjuvant chemotherapy Rare gallbladder cancer type shows specific genetic markers and traits
This case report and literature review describes the clinical management of a patient with mixed adenoneuroendocrine carcinoma of the gallbl…
A rare form of gallbladder cancer, known as GB-MANEC, was identified in a patient who underwent surgery and chemotherapy with no recurrence …
Frontiers Jun 30, 2026
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
OB/GYN & Women's Health RCT
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer. Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Jun 4, 2026
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
Infectious Disease Sys. Review
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Frontiers May 22, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
Dermatology Sys. Review
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct At-a-Glance
This review of a case report describes two patients with unresectable intraductal papillary mucinous neoplasms of the bile duct treated with…
A new three-drug combination shrank a rare bile duct tumor in one patient and stopped another from growing, offering hope for a cancer with …
Frontiers May 8, 2026
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
Oncology Meta-analysis
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer Gemcitabine and docetaxel show similar recurrence-free survival to BCG for bladder cancer
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Guérin (BCG) in pa…
A meta-analysis of 1634 patients found gemcitabine and docetaxel offered recurrence-free survival rates comparable to BCG therapy for non-mu…
May 2, 2026

All gemcitabine Articles